Latest Regulatory News

Viridis Mining and Minerals has announced a substantial upgrade to its Colossus Ionic Adsorption Clay Rare Earth Element Project, reporting a 140% increase in its JORC-compliant Mineral Resource Estimate. This positions Colossus as the largest and highest-grade IAC rare earth resource globally, with significant implications for the rare earth sector.

Emyria Limited announces key leadership shifts with Greg Hutchinson stepping up as Executive Chairman and Dr. Michael Winlo transitioning to Chief Scientific Officer, aiming to scale innovative mental health therapies amid growing demand.

Aeris Resources has completed a 70-hole drill program at its Constellation deposit, delivering impressive high-grade copper intercepts and setting the stage for a significant resource upgrade and mine permitting milestones.

Bell Financial Group has secured a significant agreement with Macquarie Bank to transfer approximately 75,000 online trading accounts, positioning Bell Direct and Desktop Broker for growth and earnings uplift in FY 2025.

Amcor plc has entered a definitive agreement to acquire Berry Global Group in a $9.9 billion all-stock transaction, aiming to create a global packaging leader. The merger, pending shareholder and regulatory approvals, is expected to close mid-2025.

Invex Therapeutics reports encouraging results from its collaboration with Tessara Therapeutics, showing Exenatide’s potential to improve neuronal survival in a 3D human brain model of Alzheimer's disease. The company maintains a stable cash position while exploring new neurological partnerships.

Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.

Evolution Mining delivered a standout December quarter with record cash flows, improved safety, and regulatory approval extending Cowal’s mine life to 2042. The company’s growth projects, including the Mungari mill expansion, are progressing ahead of schedule and under budget, positioning Evolution strongly for FY25.

LTR Pharma has inked a national distribution agreement with Symbion, positioning its innovative ED treatment SPONTAN® for broad pharmacy access across Australia ahead of its commercial launch.

Chrysos Corporation reports a robust Q2 FY25 with a 12% quarter-on-quarter and 53% year-on-year revenue increase, driven by expanding international sales and rising sample volumes. The company secured two new contracts, boosting its PhotonAssay™ footprint and maintaining strong financial health.

FMR Resources has secured GroundTruth Drilling to commence a 1,500m RC drilling campaign at its Fairfield Copper Project in New Brunswick, targeting high-grade copper-silver zones and new anomalies identified by airborne EM surveys.

Sabre Resources Ltd has identified four new uranium chargeability anomalies at its Dingo Project in the Northern Territory, expanding its exploration potential in the Ngalia Basin. The company plans to drill test these targets pending regulatory approval.